Join        Login             Stock Quote

Gilead Sciences (GILD) 4Q Earnings Beat Estimates; Shares Rise

 February 04, 2013 04:28 PM

(By Balaseshan) Gilead Sciences Inc. (NASDAQ: GILD) reported a 14.6% increase in quarterly earnings on higher product sales backed by HIV treating antiviral franchise. Results exceeded Street's expectations, sending its shares up 1.79% in aftermarket.

Earnings for the fourth quarter were $762.5 million or $0.47 per share, up from $665.1 million or $0.43 per share last year. Adjusted earnings per share (EPS) rose to $0.50 from $0.49.

Total revenue increased 18% to $2.59 billion.

Analysts, on average, polled by Thomson Reuters had expected a profit of $0.48 per share on revenue of $2.43 billion for the fourth quarter.

[Related -Can Abbvie Inc (NYSE:ABBV) Trump Gilead Sciences, Inc.'S (NASDAQ:GILD) HCV Lead?]

Product sales grew 18% to $2.51 billion, due primarily to Gilead's antiviral franchise, resulting from higher sales of Complera/Eviplera, Atripla and Truvada as well as the launch of Stribild.

Antiviral product sales increased 17% to $2.17 billion, reflecting sales growth of 20% in the U.S. and 9% in Europe. Cardiovascular product sales jumped 33% to $215.2 million. Sales of other products rose 15% to $127.7 million.

Research and development (R&D) expenses for the fourth quarter increased 9 percent. Adjusted R&D expenses rose 17 percent due primarily to the continued investment in Gilead's product pipeline, particularly in liver disease and oncology.

Selling, general and administrative (SG&A) expenses rose to $365.8 million from $346.2 million.

[Related -Three Stocks Set For FDA News In Early December]

As of December 31, 2012, Gilead had $2.58 billion of cash, cash equivalents and marketable securities, down from $9.96 billion as of December 31, 2011, due to the acquisition of Pharmasset in the first quarter of 2012. Gilead generated $3.19 billion of operating cash flow in 2012 including $705.7 million generated in the fourth quarter of 2012.

GILD closed Monday's regular session down 2.39% at $39.59. The stock has been trading between $21.91 and $41.14 for the past 52 weeks.

iOnTheMarket Premium


Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageMr. Market's Wary Outlook: Less Severe But Still Worrisome

Mr. Market’s cautious outlook of late is less acute at the moment relative to recent history, but it’s not read on...

article imageThere's One Problem With This Market Rally...

All major U.S. indices closed higher last week, logging the second week of strength following choppy read on...

article imageWill Last Week’s Relief Rally In Emerging Markets Last?

Stocks in emerging markets posted their best weekly gain in nearly four years last week. Analysts are read on...

article imageHow Much Longer Can Our Unaffordable Housing Prices Last?

Markets discover price via supply and demand: Big demand + limited supply = rising prices. Abundant supply read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.